CHINOOK THERAPEUTICS, INC. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020	Q1 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q3 FY2019 As of Sep 30, 2019	Q2 FY2019 As of Jun 30, 2019	Q1 FY2019 As of Mar 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q3 FY2018 As of Sep 30, 2018
Assets
Current assets:
Cash and cash equivalents
Restricted cash
Marketable securities
Income tax receivable
Accounts receivable
Prepaid expenses and other current assets
Total current assets

Marketable securities
Property and equipment, net and finance right-of-use asset
Property and equipment, net
Restricted cash
Operating lease right-of-use assets
Investment in equity securities
Equity method investment
Intangible assets, net
In-process research & development
Goodwill
Other assets
Total assets
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
Accrued clinical trial and manufacturing expenses
Accrued and other current liabilities
Operating lease liabilities
Finance lease liabilities – related party
Contingent value rights liability
Deferred revenue
Total current liabilities

Deferred rent
Redeemable convertible preferred stock tranche liability
Contingent value right liability
Contingent value rights liability
Contingent value rights liability - non-current
Contingent consideration liability
Deferred revenue
Deferred tax liabilities
Operating lease liabilities, net of current maturities
Finance lease liabilities, net of current maturities – related party
Other long-term liabilities
Total liabilities
Redeemable convertible preferred stock, $0.0001 par value; none and 65,000,000 shares authorized as of December 31, 2020 and 2019, respectively; none and 7,596,886 shares issued and outstanding as of December 31, 2020 and 2019, respectively; liquidation preference $0 and $26,000 as of December 31, 2020 and 2019, respectively
Stockholders’ equity:
Common stock, $0.0001 par value; 300,000 shares authorized as of June 30, 2023 and December 31, 2022; 67,079 and 65,471 shares issued and outstanding at June 30, 2023 and December 31, 2022
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Total stockholders’ equity
Total liabilities and stockholders’ equity

Comments